SCHEMBL2679720

SCHEMBL2679720

Cc1cn(-c2ccc(NC(=O)c3ccc(C)c(NC(=O)C=Cc4cccnc4)c3)cc2C(F)(F)F)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 7/20 0.50
KIT P10721 8/20 0.48
PDGFRA P16234 7/20 0.48
BRAF P15056 4/20 0.48
CSF1R P07333 4/20 0.48
LCK P06239 4/20 0.48
LYN P07948 4/20 0.48
PDGFRB P09619 4/20 0.48
FLT3 P36888 4/20 0.48
DDR2 Q16832 4/20 0.48
BCR P11274 2/20 0.48
EPHB2 P29323 2/20 0.48
HCK P08631 2/20 0.48
EPHB6 O15197 1/20 0.48
CA12 O43570 1/20 0.48
CACNA1F O60840 1/20 0.48
SLC22A3 O75751 1/20 0.48
STK10 O94804 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077754 1.00 ABL1 (0.50) ABL1KITPDGFRABRAFCSF1R
SCHEMBL10077762 0.92 BRAF (0.49) ABL1KITBRAFCSF1RLCK
SCHEMBL2679904 0.92 BRAF (0.49) ABL1KITBRAFCSF1RLCK
SCHEMBL2679206 0.88 CSF1R (0.57) KITPDGFRABRAFCSF1RDDR2
SCHEMBL10077755 0.88 CSF1R (0.57) KITPDGFRABRAFCSF1RDDR2
SCHEMBL2679133 0.85 ABL1 (0.69) ABL1KITPDGFRABRAFCSF1R
SCHEMBL10077601 0.84 BRAF (0.59) ABL1KITBRAFCSF1RHCK
SCHEMBL2679275 0.84 BRAF (0.59) ABL1KITBRAFCSF1RHCK
SCHEMBL2679244 0.84 CSF1R (0.54) KITPDGFRABRAFCSF1RDDR2
SCHEMBL10078752 0.84 CSF1R (0.54) KITPDGFRABRAFCSF1RDDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR ABL1 1/4885KIT 399/4885PDGFRA 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.